Jubilant Pharmova Q1 results show revenue fell from 1682.4 crores to 1595.5 crores, a -5.17% decrease in growth. EPS rise from ₹-6.15 to ₹0.40, up by 106.50%.
First, Let’s Begin with Quarter-on-Quarter Basis:
Jubilant Pharmova shared its Q1 results on Wednesday. They earned 1595.5 crores in revenue this quarter, but that’s less than the 1682.4 crores they made last quarter. Unfortunately, the company’s growth decreased by -5.17 percent when comparing the two quarters.
In terms of profits, the company’s PAT (Profit After Tax) for this quarter was 6.4 crores, up from -97.9 crores in the previous quarter. Their quarter-to-quarter growth increased by 106.54 percent.
The company’s EPS (Earnings Per Share) this quarter is ₹0.40, which is an increase of 106.50% from the ₹-6.15 EPS in the previous quarter.
Now, Let’s Analyze the Results on a Year-over-Year Basis:
The company made a total revenue of 1595.5 crores this year (2023), which is 9.06 percent higher than last year’s total revenue of 1463 crores.
This year’s PAT (Profit After Tax) is 6.4 crores, which is also -86.41% lower than last year’s PAT of 47.1 crores.
The EPS (Earnings Per Share) for this year is ₹0.40, which is -86.49% less than the EPS of ₹2.96 earned last year.
Jubilant Pharmova Share Dividend Announcement / Record Date:
The record date for the dividend has not arrived yet.
About Jubilant Pharmova:
Jubilant Pharmova Limited functions as a pharmaceutical company, providing a range of products and services throughout the pharma value chain. Their offerings encompass the manufacturing and supply of radiopharmaceuticals, development of therapies, and drug discovery and development services.
Download the Full PDF of Jubilant Pharmova Q1 Results: Click Here
For more of the Latest News, Click Here